CERENOVUS Launches EMBOGUARD™ Balloon Guide Catheter to Use In the Treatment of Acute Ischemic Stroke

EMBOGUARD™ Balloon Guide Catheter with colorful brand elements.

EMBOGUARD™ is the first balloon guide catheter from CERENOVUS and is the latest device to join the CERENOVUS Stroke Solutions™ suite of technologies

IRVINE, CA – February 7, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices Companies,* today announced the launch of EMBOGUARD™, a next generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.

Ischemic strokes, caused by the formation of a local blood clot or an embolus that travels to a vessel in the brain and obstructs blood supply, account for 85%1 of all strokes worldwide. Mechanical thrombectomy (MT), a minimally invasive procedure to remove a clot, is the recommended treatment option for acute ischemic stroke.2 The EMBOGUARD™ Balloon Guide Catheter is designed to optimize removal of clots by controlling blood flow locally during MT procedures.3 Balloon guide catheters increase first pass recanalization, reduce procedure time and reduce the odds of clot fragments breaking off and causing distal emboli.4 Distal emboli in an endovascular procedure can result in new ischemic events.

“Without timely and effective treatment of stroke, patients can suffer from lifelong disability or dependency,” said David Fiorella MD, PhD, Director of Cerebrovascular Center, Stony Brook University Hospital. “The benefits of balloon guide catheters are becoming increasingly recognized for their ability to maximize patient outcomes. By adding this innovation to their Stroke Solutions portfolio, CERENOVUS will be arming physicians with the tools they need to better serve our patients, potentially increasing the chances to live a functional and fulfilling life post-stroke.”

EMBOGUARD™ is the latest addition to join CERENOVUS Stroke Solutions™ - a suite of technologies designed with compatibility in mind to assist physicians in performing mechanical thrombectomy procedures. Launched in 2020, CERENOVUS Stroke Solutions now includes the EMBOTRAP® III Revascularization Device, the PROWLER™ EX Microcatheter, the CERENOVUS™ Large Bore Catheter as well as both the EMBOGUARD™ Balloon Guide Catheter and the CEREBASE™ Guide Sheath.

“We’re proud to announce the addition of EMBOGUARD into our family of CERENOVUS Stroke Solutions,” said Mark Dickinson, Worldwide President, CERENOVUS. “The addition of this device to our portfolio of technologies provides physicians with an innovative and comprehensive set of tools to treat their patients, building on our commitment to changing the trajectory of stroke.”

The EMBOGUARD™ Balloon Guide Catheter will debut for the first time at the International Stroke Conference in New Orleans, Louisiana from February 9-11, 2022.

For more information about CERENOVUS, connect with us on Twitter and LinkedIn.

CERENOVUS, part of Johnson & Johnson Medical Devices Companies, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit www.cerenovus.com and connect on LinkedIn and Twitter.

About Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life. For more information, visit www.jnjmedtech.com.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding CERENOVUS EMBOGUARD™. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of CERENOVUS, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither CERENOVUS, any of the other Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses. CERENOVUS is part of the Johnson & Johnson Medical Devices Companies.

  1. Ischaemic stroke. Stroke Association. Stroke.org.uk. www.stroke.org.uk.
  2. Parthasarathy R and Gupta V. Ann Indian Acad Neurol. 2020 Jan-Feb 23(1): 13–19. www.ncbi.nlm.nih.gov. Last accessed online September 2020.
  3. EMBOGUARD Simulated Clot Retrieval Report. 500756583 | Rev: A.6. Released: 15-Jul-2021. State: Released. CN: 231147
  4. Brinjikji, Waleed, et al. Impact of balloon guide catheter on technical and clinical outcomes: a systematic review and metaanalysis. J NeuroIntervent Surg. 2017. jnis.bmj.com.

Media Contact:
Samantha Yakal-Kremski
[email protected]